Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

The Hospitalization-Related Costs of Adverse Events for Novel

Cancers, Free Full-Text

Frontiers Second-Generation Antiandrogens: From Discovery to

Prostate Cancer Treatment Market Size and Share

Cancers, Free Full-Text

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival

Androgen receptor pathway inhibitors, prostate cancer, and older

The treatment landscape of metastatic prostate cancer - ScienceDirect

Treatments for Metastatic Hormone-sensitive Prostate Cancer

Androgen receptor pathway inhibitors, prostate cancer, and older